The data represent a potentially transformative proof-of-concept for icovamenib in T1D, but the small sample size (n=5 for the primary cohort), open-label design, and prior FDA clinical hold introduce significant uncertainty. Monitor the ADA presentation in June 2026 for the full dataset and any partnership or financing announcements that could de-risk the program.
Price Chart
Executive Summary
Biomea Fusion reported positive 52-week Phase 2 COVALENT-112 topline data for icovamenib in type 1 diabetes (T1D), showing a 52% mean increase in C-peptide AUC at Week 12 (p<0.001) in recently diagnosed patients (n=5), with effects largely preserved through Week 52 (~7% decline from baseline). The company plans a new Phase 2 trial in H2 2026 with extended dosing and potential combination with an immunosuppressant. The data are early-stage, open-label, and from a small sample (n=5 for the primary cohort), limiting statistical reliability.
Key Facts
- Phase 2 COVALENT-112 trial of icovamenib in T1D showed a 52% mean increase in C-peptide AUC at Week 12 (p<0.001) in Cohort 1 patients (diagnosed ≤3 years, 200 mg dose, n=5).
- Mean C-peptide AUC was largely preserved through Week 52 with only ~7% decline from baseline after 12 weeks of dosing.
- A dose response was observed with 200 mg demonstrating greater activity than 100 mg.
- Study enrollment was interrupted in May 2024 due to an FDA clinical hold (subsequently resolved), resulting in approximately half the originally intended patient population.
- A planned placebo-controlled Part 2 of the study was not completed.
- Company plans to initiate a new Phase 2 trial in H2 2026 with extended dosing (up to 6-12 months) and potential combination with an immunosuppressive agent at four U.S. academic centers.
- Comprehensive dataset to be presented at the American Diabetes Association (ADA) Scientific Sessions in June 2026.
Financial Impact
No financial figures reported; pre-revenue clinical-stage biotech with $125M market cap.
Risk Factors
- Very small sample size (n=5 for the primary efficacy cohort) limits statistical reliability and generalizability.
- Open-label trial design with no placebo control introduces potential bias.
- Prior FDA clinical hold (May 2024) and incomplete enrollment raise regulatory risk.
- Pre-revenue company with $125M market cap may require additional financing to fund planned Phase 2 trial.
- Data are early-stage; durability and safety in larger, controlled studies are unproven.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-183710 |
| Document: d142809dex991.htm | 0001193125-26-183710 |
| Document: 0001193125-26-183710-index-headers.html | 0001193125-26-183710 |
| Document: 0001193125-26-183710-index.html | 0001193125-26-183710 |
| Document: 0001193125-26-183710.txt | 0001193125-26-183710 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6424 (−22.97%) |
Oct 13, 2026 14d ago | Press Release | $0.8340 $0.6901 | ▼ −17.25% | ▼ −17.71% | $0.6424 (−22.97%) |
Sep 23, 2026 4w ago | Press Release | $1.44 $1.33 | ▼ −7.64% | ▼ −6.96% | $0.6424 (−55.39%) |
Sep 22, 2026 5w ago | 424B5 | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6424 (+55.39%) |
Sep 22, 2026 5w ago | Press Release | $1.44 $1.33 | ▲ +7.64% | ▲ +6.96% | $0.6424 (+55.39%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.17 $1.18 | ▲ +0.85% | ▲ +0.18% | $0.6424 (−45.09%) |
Jun 5, 2026 20w ago | Press Release | $1.15 $1.20 | ▲ +4.35% | ▲ +2.24% | $0.6424 (−44.14%) |
May 11, 2026 24w ago | 8-K | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6424 (−59.34%) |
May 11, 2026 24w ago | Press Release | $1.58 $1.25 | ▼ −20.89% | ▼ −20.96% | $0.6424 (−59.34%) |
Apr 28, 2026 26w ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −4.96% | $0.6424 (−58.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers